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AIM AND OBJECTIVE 
 
 
The basic aim of this project is to conduct the Bioequivalence study of an 
Antidepressant, in accordance with the regulatory authority. The BE study is conducted 
on a test product, ‘T’and reference product ‘R’. ‘T’, and ‘R’are oral Tablet containing 
drug Cinitapride. In a dose of 150mg. Drug Cinitapride is an Gastrointestinal motility 
treatment drug.  
The study objectives included: 
• Assessment of the bioavailability of test  product A while comparing with a 
reference product B in 6 normal, adult, human subjects under fasting 
condition. The bioequivalence assessed is to be assessed under  following 
pharmacokinetic Parameters: 
¾ AUC0-t,  
¾ AUC0-∞,  
¾ Cmax, 
¾  Tmax,  
¾ Kel, and  
¾ t1/2. 
• Monitoring of the adverse events and ensure safety of the subjects. 
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LIST OF ABBREVIATIONS 
 
 
 
 
 
 
 
AE Adverse Event 
ANOVA  Analysis of Variance 
ANDA Abbreviated new drug application 
AUC  Area under the plasma concentration versus time curve 
AUC_Extrap
olated (%) 
Percentage Area Under the Plasma Concentration extrapolated 
from AUC0-t to AUC0-∞ 
AUC0-∞ 
The area under plasma concentration versus time curve from time 
zero to infinity 
AUC0-t 
The area under the plasma concentration versus time curve from 
time zero to the last measurable concentration 
BA/BE Bioavailability / Bioequivalence 
BMI Body Mass Index 
CDSCO Central Drug Standard Control Organization 
cGMP Current good manufacturing practices 
CI Clinical Investigator  
C.I. Confidence interval 
Cmax Concentration Maximum 
CPB Clinical Pharmacokinetics and Biopharmaceutics 
CRA Clinical Research Associate 
CRF Case Report Form 
CRF,  Corticotrophin-releasing factor 
C.V. Coefficient of variance 
D Day 
Dept. Department  
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CG Electro Cardiogram 
ELISA Enzyme linked immune sorbant assay 
FDA Food and drug administration 
XL Extended Release 
GCP Good Clinical Practice 
GGTP Gamma Glutamyl Transamino Peptidase 
GMP Good manufacturing 
HBsAg Hepatitis B surface Antigen  
HCT Hematocrit 
HCV Hepatitis C virus 
HCl Hydrochloride 
HIV Human Immuno Deficiency Virus 
Hr/Hrs Hours 
I.D Identity 
ICF Informed Consent Form 
ICH International Conference on Harmonization 
ICMR Indian Council of Medical Research 
IEC Independent Ethics Committee 
IP(s) Investigational Product(s) 
IL Immediate release 
K3EDTA Tri-potassium Ethylene Diamine Tetra Acetic acid 
Kel  First order rate constant associated with the terminal (log-linear) 
portion of the curve 
Kg Kilogram 
LLOQ Lower limit of quantification 
LSM Least Square Means 
LC-MS-
MS 
Tandem mass spectroscopy 
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M Meter  
ME Medical Examination  
MR Modified Release 
Mg Milligram 
ml/mL Milliliter  
NA Noradrenaline 
ng.hr/m
L 
Nanogram. Hour/milliliter 
No. Number 
PCV Packed Cell Volume  
PI Principal Investigator 
PK Pharmacokinetic  
PD Pharmacodynamic 
QC Quality control 
RLD Reference listed drug 
RPM Rotation per Minute 
SAE Serious Adverse event 
SAS Statistical Analysis Software  
SGOT Serum Glutamate Oxaloacetate Transaminase 
SGPT Serum Glutamate Pyruvate Transaminase 
SOP Standard Operating Procedure 
TrkB kinase-linked receptor 
T1/2 Elimination Half-life 
Tmax Time at Concentration Maximum 
ULOQ Upper limit of Quantification 
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1. INTRODUCTION 
 
Bioavailability is used to describe the fraction of an administered dose of 
medication that reaches the systemic circulation, one of the principal properties of the 
drugs. By definition, when the drug is administered intravenously, its bioavailability is 
100%. However when a medication is administered via other routes (such as by mouth), 
its bioavailability decreases (due to incomplete absorption and first-pass metabolism). 
Bioavailability is one of the essential tools in pharmacokinetics, as bioavailability must 
be considered when calculating dosages for non-intravenous routes of administration. 
                Bioavailability and bioequivalence of drug products, and drug product 
selection have emerged as critical issues in pharmacy and medicine during the last three 
decades. Concern about lowering health care costs is resulted in a tremendous increase 
in the use of generic drug products; currently about one half of all prescriptions written 
are for drugs that can be substituted with a generic product. 
                 This phenomenal growth of the generic pharmaceutical industry and the 
abundance of multisource products have prompted some questions among many health 
professionals and scientists regarding the therapeutic equivalency of these products. 
Inherent in the currently accepted guidelines for product substitution is the assumption 
that a generic drug considered to be bioequivalent to a brand-name drug would elicit 
the same clinical effect. 
                Numerous papers in the literature indicate that there is concern that the 
current standards for approval of generic drugs may not always ensure therapeutic 
equivalence. The availability of different formulations of the same drug substance 
given at the same strength and in the same dosage form poses a special challenge to 
health care professionals.  
                If the size of the dose to be administered is same, then bioavailability of a 
drug from its dosage form depends upon three major factors: 
1. Pharmaceutical factors related to physiochemical properties of the drug and 
characteristics of dosage form. 
2. Patient related factors 
3. Route of administration. 
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           If the goal is to compare the two formulations of same drug then the 
experimental design should maintain the remaining factors constant. The resultant 
bioavailability may differ with respect to the amount absorbed, the rate of absorption or 
both. The bioavailability fraction f is the fraction of the administered dose that enters 
systemic circulation. 
                             f = bioavailable dose / administered dose  
 
Bioavailability reflects the extent of the systemic availability of the active 
therapeutic moiety and is generally assessed by measuring the ‘area under the 
concentration time curve’ (AUC), the peak plasma concentration (Cmax) and the 
time to reach Cmax (Tmax). The extent of the systemic availability is determined 
by the extent of drug absorbed from the site of administration. For a drug that 
obeys linear pharmacokinetics, the AUC and Cmax values increase 
proportionately with the dose. Consequently, if two formulations / dosage form 
of the same drug exhibit comparative AUC values, they are considered to have 
similar systemic availability. The bioavailability of an oral dosage form or a drug 
is generally compared with an intravenous solution (100% standard), to 
determine the absolute bioavailability. 
¾ COMPARATIVE BIOAVAILABILITY: A UNIVERSAL APPROACH:  
 Most bioavailability studies, whether for a new or generic product, possess a 
common theme.  A test is conducted to identify the quantitative nature of a 
specific product comparison.  This comparison for a new drug may be, for 
example, to assess the performance of an oral formulation relative to that of an 
intravenous dose, or perhaps the performance of a modified-release formulation 
in comparison to a conventional capsule.  For a generic product, it is typically a 
comparison of a competitive formulation with a reference product.  
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Such commonality surrounding comparative bioavailability studies suggests                     
a universal experimental approach 
 
 ttime infinity (AUC∞) is the extrapolated area based on the AUCt 
and the terminal constant (λz).                
 
profiles are the area under the curve (AUC) and the maximum observed 
concentration (Cmax); the former customarily includes the AUC to the last 
sampling time in a trial (AUCt) and the extrapolated total AUC to time 
infinity (AUC∞). The time at the maximum concentration (Tmax) is also of 
some minor interest.  After obtaining the profiles in a comparative trial, and  
 
 
 
 
 Figure 1: Illustration of the key metrics in a comparative 
bioavailability trial showing, for example, Test and Reference products.  The 
maximum concentration (Cmax) occurs at the Tmax. The AUCt is the total 
area under the concentration versus time profile to the last sampling time. 
The area to ccomputing the metrics, conclusions need to be reached 
regarding the comparison. Statistical methods are applied to test if the 
metrics are sufficiently similar to be considered equivalent.  When the 
metrics are deemed equivalent, the drug concentration profiles are regarded 
as fundamentally the same. To achieve this equivalence, the study products' 
geometric mean ratios (eg. AUC test/AUC reference), as well as their 
projected 90% confidence intervals for the population mean ratio, must be 
located within an 80 to 125% window.  For the maximum concentration 
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(Cmax) some regulatory agencies consider it adequate if only the mean ratios 
are within the interval   
 
  
Figure 2: An illustration of the statistical criteria to be satisfied to gain 
equivalence status in a comparative bioavailability assessment.  For example, in 
a bioequivalence trial, the geometric mean ratio for the test/reference Cmax 
(GMR Cmax) must be located between 0.8 and 1.25.  The GMR AUC's (whether 
AUCt or AUC∞) and their computed 90% confidence intervals must reside 
completely within the 0.8 to 1.25.  
¾ BIOEQUIVALENCE:  
                                    Bioequivalence gained increasing attention during the last 
40 years after it became evident that marketed products having the same 
amounts of the drug may exhibit marked differences in their therapeutic 
responses. Generally, these differences were well correlated to dissimilar drug 
plasma levels caused mainly by impaired absorption. Now a considerable body 
of evidence has accumulated indicating that drug response is better correlated 
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with the plasma concentration or with the amount of drug in the body than with 
the dose administered. Consequently, on the basis of simple pharmacokinetic 
concepts and parameters, bioavailability and bioequivalence studies have been 
established as acceptable surrogates for expensive, complicated and lengthy 
clinical trials, and are used extensively worldwide to establish and ensure 
consistent quality and a reliable, therapeutically effective performance of 
marketed dosage forms. 
           The present day bioequivalence studies are too complicated, expensive 
and difficult to be carried out. Two of the reasons for this difficulty are the need for 
many healthy volunteers and withdrawing 10-20 blood samples from an indwelling 
catheter from each volunteer spanning over a long period of time. Same procedure has 
to be repeated after a washout period, substituting the reference and test samples in the 
volunteers. All the samples have to be chemically analyzed and the collected data 
subjected to elaborate statistical analysis. The parameter 'area under the curve' can have 
nearly the same values for vastly bioinequivalent products as it reflects only the total 
amount of drug reaching the systemic circulation. 
                         Bioequivalence studies compare both the rate and extent of absorption 
of various multisource drug formulations with the innovator (reference) product, on the 
basis that if two formulations exhibit similar drug concentration-time profiles in the 
blood/plasma, they should exhibit similar therapeutic effects.  
Three situations have thus been defined in which bioequivalence studies are required 
• When the proposed marketed dosage form is different from that used in pivotal 
clinical trials,  
• When significant changes are made in the manufacture of the marketed 
formulation and  
• When a new generic formulation is tested against the innovator’s marketed 
product.  
Comparative evidence may require not only studies in a fasting condition, 
but following a specified meal. The latter permit drug formulations to be 
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evaluated under "stressed conditions". If it is shown that competitive products 
are bioequivalent under both fasting and fed conditions, there is greater 
confidence that they are therapeutically equivalent when used in patients.  
Bio-equivalent simply means that one brand or dosage form of a drug or 
supplement is equivalent to a reference brand or dosage form of the same drug 
or supplement in terms of various bioavailability parameters measured via in-
vivo testing in human subject. Bio-equivalence cannot be claimed based on in-
vitro testing only or on the basis of animal studies only. Bio-equivalence of 
human drugs must be determined in humans via established measures of 
bioavailability. By the same token animal drugs must be tested for bio-
equivalence in the animal species for which the drug in intended. 
Once bio-equivalence has been established via bioavailability testing in a 
statistically significant manner subsequent batches of the same product are 
deemed bio-equivalent based on in-vitro measures such as drug dissolution. 
There is no such thing as increased bio-equivalence. The statement of 
increased bio-equivalence makes no sense. A product can be either bio-
equivalent or bio-inequivalent A product can’t be more bio-equivalent or less 
bio-equivalent.   
¾ Pharmacokinetic Measurement:  
Direct (e.g., rate constant, rate profile) and indirect (e.g., Cmax, Tmax, 
mean absorption time, mean residence time, Cmax normalized to AUC) 
pharmacokinetic measurements are limited in their ability to assess rate of 
absorption.  From these direct or indirect measurements of absorption rate to 
measures of systemic exposure. Cmax and AUC can continue to be used as 
measures for product quality BA and BE, but more in terms of their capacity to 
assess exposure than their capacity to reflect rate and extent of absorption.   
• Before Peak concentration:  
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For orally administered immediate-release drug products, BE may 
generally be demonstrated by measurements of peak and total concentration. An 
early concentration measure may be indicated on the basis of appropriate clinical 
efficacy/safety trials and/or pharmacokinetic / pharmacodynamic studies that call 
for better control of drug absorption into the systemic circulation (e.g., to ensure 
rapid onset of an analgesic effect or to avoid an excessive hypotensive action of 
an antihypertensive). In this recommends use of partial AUC as a Before Peak 
concentration. The partial area should be truncated at the population median of 
Tmax values for the reference formulation. At least two quantifiable samples 
should be collected before the expected peak time to allow adequate estimation 
of the partial area.  
 
• Peak concentration:  
Peak concentration should be assessed by measuring the peak drug 
concentration (Cmax) obtained directly from the data without interpolation.  
• Total concentration:  
For single-dose studies, the measurement of total concentration should be: 
Area under the plasma/serum/blood concentration-time curve from time zero to 
time t (AUC0-t), where t is the last time point with measurable concentration for 
individual formulation. Area under the plasma/serum/blood concentration-time 
curve from time zero to time infinity (AUC0-∞), where AUC0-∞ = AUC0-t + Ct/z, 
Ct is the last measurable drug concentration and z is the terminal or elimination 
rate constant calculated according to an appropriate method. The terminal half-
life (t1/2) of the drug should also be reported. 
The following pharmacokinetic parameters are required for submission: 
z Plasma concentrations and time points  
z Subject, period, sequence, treatment  
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z AUC0-t, AUC0-∞, Cmax, Tmax, z , and t1/2.  
z Intersubject, intrasubject, and/or total variability, if available  
z Cmin (concentration at the end of a dosing interval),  
z Cav (average concentration during a dosing interval),  
z Degree of fluctuation [(Cmax-Cmin)/Cav], and  
z Swing [(Cmax- Cmin)/Cmin] if steady-state studies are employed.  
The following statistical information required for AUC0-t, AUC0-∞, and Cmax: 
z Geometric mean  
z Arithmetic mean  
z Ratio of means  
z Confidence intervals  
 Logarithmic transformation should be provided for measures used for BE 
demonstration. 
Rounding off of confidence interval values: 
Confidence interval (CI) values should not be rounded off; therefore, to pass a 
CI limit of 80-125, the value should be at least 80.00 and not more than 125.00. 
¾ GENERAL CONCEPTS OF DESIGN AND CONDUCT OF 
STUDIES: 
The design and conduct of the study should follow EC-rules for Good 
Clinical Practice, including reference to an Ethics Committee. 
As recommended by the US FDA (1992), in most bioequivalence trials, a 
“test” formulation is compared with the standard / innovator “reference” 
formulation, in a group of normal, healthy subjects (18-55 yr), each of whom 
receive both the treatments alternately, in a crossover fashion (two-period, two-
treatment crossover design), with the two phases of treatment separated by a 
“washout period” of generally a week’s duration, but may be longer (a minimum 
time equivalent to 5 half-lives) if the elimination half-life of the drug is very 
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long. The treatment is assigned to each subject, randomly, but an equal number 
of subjects receive each treatment in each phase. Thus, in case of two treatments 
A and B, one group gets the treatment in the order AB and the second group in 
the reverse order BA. This is done to avoid the occurrence of possible sequence 
or period effects. A similar allocation is done in case of a three-treatment 
crossover design (three-period, three-treatment crossover design). 
For several drugs a great inter-subject variability in clearance is observed. 
The intra-subject coefficient of variation (approximately 15%) is usually 
substantially smaller than that between subjects (approximately 30%), and 
therefore, crossover designs are generally recommended for bioequivalence 
studies. 
The primary advantage of the crossover design is that since the treatments 
are compared on the same subject, the intersubject variability does not contribute 
to the error variability. If the drug under investigation and/or its metabolites has 
an extremely long half-life, a parallel group design may be indicated. In a 
parallel group design, subjects are divided randomly into groups, each group 
receiving one treatment only. Thus, each subject receives only one treatment. In 
a parallel design, although one does not have to worry about sequence, period or 
carry over effects, or dropouts during the study, the inter-subject variability 
being very high, the sensitivity of the test is considerably reduced, thus requiring 
a larger number of subjects compared to a crossover design, to attain the same 
sensitivity. 
Inherent in both the crossover and parallel designs are the three fundamental 
statistical concepts of study design, namely  
• Randomization  
• Replication and Error control.  
• Randomization 
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It implies allocation of treatments to the subjects without selection bias. 
Consequently, randomization is essential to determine an unbiased estimate of 
the treatment effects. 
• Replication 
 It implies that a treatment is applied to more than one experimental unit 
(subject) to obtain more reliable estimates than is possible from a single 
observation and hence provides a more precise measurement of treatment 
effects. The number of replicates (sample size) required will depend upon the 
degree of differences to be detected and inherent variability of the data. 
Replication is used concomitantly with “Error control” to reduce the 
experimental error or error variability.  
More commonly used replicated crossover designs to compare two formulations 
are:  
z Four-sequence and two-period design (Balaam’s design):   
z Two-sequence and four-period design:  
z Four-sequence and four-period design:         
z Two-sequence and three-period design           
z Crossover design for three medications (Williams’ design):  
z Crossover design for four medications (Williams’ design):  
 
 
 
¾ Crossover design for two medications (T – test; R = reference): 
• 2x2 crossover design: 
This is a conventional not-replicated design with two formulations, two periods, 
two sequences that may be represented as follows: 
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Each individual is randomly assigned to RT or TR sequence in two dosage periods. 
That is, individuals assigned to RT (TR) sequence receive formulation R (T) in the first 
dosage period and formulation T (R) in the second dosage period. 
Randomization for a 2x2 crossover study may be carried out through tables of random 
numbers or randomization procedures implemented by statistical software. 
¾ Replicated crossover design: 
This design is recommended for bioequivalence studies of formulations with 
modified-release dosage or highly variable products (intra-individual variation 
coefficient ≥30%), including the quick-release, and modified-release ones and other 
oral administration products. 
The same test and reference formulation batches shall be used for this design for 
replicated administration. The periods shall be sufficiently spaced (washout) to assure 
non-existence of carryover effects. 
More commonly used replicated crossover designs to compare two formulations are: 
¾ Four-sequence and two-period design (Balaam’s design): 
 
¾ Two-sequence and four-period design: 
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¾ Four-sequence and four-period design: 
 
 
¾ Two-sequence and three-period design         
 
 
¾ Crossover design for three medications (Williams’ design): 
(Williams’ design with T1 = test 1, T2 = test 2, R = reference) 
In order to compare three formulations of a drug, there are a total of three 
possible comparison pairs among formulations: formulation 1 versus formulation 2, 
formulation 1 versus formulation 3, and formulation 2 versus formulation 3.  
 
 
 
¾ Crossover design for four medications (Williams’ design): 
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• Wash out period: 
Subsequent treatments should be separated by periods long enough to eliminate 
the previous dose before the next one (wash-out period). Sampling should be done long 
enough to cover at least 80% of the area under the plasma concentration curve as 
extrapolated to infinity. The extrapolation should be based on knowledge of the 
dominating elimination half-life. 
• Subjects: 
 
The number of subjects required is determined by the error variance associated 
with the primary characteristic to be studied (as estimated from a pilot experiment, 
from previous studies or from published data), by the significance level desired, and by 
the deviation from the reference product compatible with bioequivalence and with 
safety and efficacy. It should be calculated by appropriate methods and should not be 
smaller than 12. The deviation allowable usually is 20%. The number of recruited 
subjects should always be justified. 
       Bioavailability studies generally will be performed with healthy volunteers. If 
feasible, they should belong to both sexes and be between 18 and 55 years old to 
minimize intra- and inter-individual variation subjects should be standardized as much 
as possible and acceptable. They should preferably be fasting at least during the night 
before administration of the products or they should take a standard meal at a specified 
time before the treatment. Time and preferably composition of meals taken after the 
treatment should be standardized. Because fluid intake may profoundly influence 
gastric passage, it should be strictly standardized and specified. The subjects should not 
take other medicines during a suitable period before and during the study. They should 
preferably abstain from food and drinks, which may interact with circulatory, gastro-
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intestinal, liver or renal function (e.g. alcoholic or xanthine-containing beverages). 
Preferably they should be non-smokers. If smokers are included they should be 
identified as such. In some cases (e.g. study of high clearance substances) even posture 
or physical activity may have to be standardized. 
• Reference and test product: 
All investigated products must have been prepared in accordance with GMP-
rules. Batch control results of the test product should be reported. Generic products, 
being pharmaceutical equivalents or alternatives are normally compared with the 
corresponding form of a well-established “Innovator” medicinal product (reference 
product). The applicant should justify the choice of reference product. The test product 
will mostly originate from a test batch. After scale-up samples of the product the 
production batches should be compared with those of the test batch, and they should 
show the same dissolution rate “in vitro” in a discriminatory test. The study sponsor 
will have to retain a sufficient number of product samples for the accepted shelf life 
plus one year to allow repetition of “in vitro” and “in vivo” studies at the request of the 
authority. 
Data analysis: 
The aim of a bioequivalence study is to demonstrate equivalence within the 
acceptance range regarded as clinically relevant. The primary concern in 
bioequivalence assessment is to limit the risk of erroneously accepting bioequivalence. 
Only statistical procedures, which do not exceed the nominal risk of 5%, can be 
approved, and among them the one with the smallest risk of erroneously rejecting 
bioequivalence should be selected. 
In case of a parametric approach the inclusion of the classical 90% confidence 
interval for the chosen measure of relative bioavailability within the acceptance range 
(bioequivalence range) is the procedure of choice. This procedure is equivalent to the 
rejection of two one sided hypotheses concerning bioinequivalence at the nominal 5%-
level. According to present views concentrations and concentration-related 
characteristics (e.g. AUC, MRT) should preferably be tested after logarithmic 
transformation. If the assumption of a lognormal (AUC, Cmax) distribution or normal 
(tmax) distribution in the parametric approach is doubtful, a corresponding non-
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parametric approach is recommended. This approach may also be chosen as the general 
statistical approach to evaluate all bioavailability characteristics throughout a given 
study. Assumptions on the design or statistical analysis should be discussed. 
• “In vitro” Dissolution 
The results of “in vitro” dissolution tests, obtained with the batches of test and 
reference products that were used in the bioavailability or bioequivalence study should 
always be reported. The specifications for the “in vitro” dissolution of the product 
should be derived from the dissolution profile of the batch that was found to be 
bioavailable or bioequivalent. 
• Reporting 
The report of a bioavailability or bioequivalence study should give the complete 
documentation of its protocol, conduct and evaluation complying with GCP-rules. This 
implies that the signature of the study monitor attests the authenticity of the whole of 
the report. The responsible investigators should sign for their respective sections of the 
report. Names and affiliations of the responsible investigators, site of the study and 
period of its execution should be stated. The names and batch numbers of the products 
used in the study as well as the composition(s) of the test product(s) should be given. In 
addition the applicant may submit a signed statement, confirming the identity of the test 
product with the product, which is submitted for registration. All results should be 
presented in a clear way. The way of calculating the characteristics used (e.g. AUC) 
from the raw data should be specified. Deletion of data should be justified. If results are 
calculated using pharmacokinetic models the model and the computing procedure used 
should be justified. Individual plasma concentration/time curves should be drawn on a 
linear/linear, and facultatively also on a lin/log scale. All individual data and results 
should be given, also of eventually dropped-out subjects. Dropout and withdrawal of 
subjects should be reported and accounted for. A representative number of 
chromatograms should be included. The analytical validation report should be reported. 
 
• Absolute bioavailability:  
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 It is the fraction effectively absorbed after extravascular administration of a 
‘Drug’, when compared to the administration of the same ‘Drug’ intravenously, which 
has, by definition, a 100%bioavailability.  
• Adverse Event: 
  An adverse event is any untoward medical occurrence in clinical 
investigation subject administered a pharmaceutical product and that does not 
necessarily have a causal relationship with this treatment. 
• Analysis Of Variance (ANOVA): 
   ANOVA is a statistical technique to identify sources of variance and 
estimate the degree of variability. In most bioavailability studies, there are three readily 
identified sources of variance namely formulation (Treatment), subject and period; 
hence it is a 3-way ANOVA.  
• Area under the curve (AUC):   
  Area under the curve is the total area under the biological fluid (serum, blood, 
etc.) concentration-time curve as determined by the Trapezoidal rule.  
• Bioavailability studies:  
  It involves the determination of ‘Drug’ concentration in the blood or urine. 
Concern with how quickly and how much of a ‘Drug’ appears in the blood after a 
specific dose is administered.  
• Cmax: 
  This is the maximum ‘Drug’ concentration achieved in systemic circulation 
following ‘Drug’ administration.  
• Case Report Form:  
 A printed, optical or electronic document designed to record all of the 
protocol-required information to be reported to the sponsor on trial subject. 
• Essentially similar products: 
 “A proprietary medicinal product will be regarded as essentially similar to 
another product if it has the same qualitative and quantitative composition in terms of 
active principles (substances), and the pharmaceutical form is the same and, where 
necessary, bioequivalence with the first product has been demonstrated by appropriate 
 
 
 
31 
bioavailability studies carried out.”  Pharmaceutical products essentially similar to an 
“innovator” product are usually designated as “generics” or “branded generics”.  
 
 
• Good Clinical Practice: 
 
 A standard for the design, conduct, performance, monitoring, auditing, 
recording, analyses and reporting of clinical trials that provides assurance that the data 
and reported results are credible and accurate, and that the rights, integrity, and 
confidentiality of trial subjects are protected. 
• Informed Consent:  
 A process by which a subject voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all aspects of the trial are 
relevant to the subject’s decision to participate. Informed consent is documented by 
means of a written, signed, and dated informed consent form. 
• Investigational Product: 
 A pharmaceutical form of an active ingredient being tested or used as a 
reference in a clinical trial, including a product with a marketing authorization when 
used or assembled (formulated or packaged) in a way different from the approved form, 
or when used for an unapproved indication, or when used to gain further information 
about an approved use. 
• Pharmaceutical alternatives: 
  Medicinal products are pharmaceutical alternatives if they contain the same 
therapeutic moiety but differ in chemical form of that moiety or in the dosage form or 
strength. The therapeutic moiety may be used in the form of salts, esters, etc. 
• Pharmaceutical equivalents:  
  Medicinal products are pharmaceutical equivalents if they contain the same 
amount of the same active substance(s) in the same dosage forms that meet the same or 
comparable standards. Pharmaceutical equivalence does not necessarily imply 
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bioequivalence as differences in the excipients and/or the manufacturing process can 
lead to faster or slower dissolution and/or absorption. 
• Protocol:  
 A document that describes the objective(s), design, methodology, statistical 
consideration, and organization of a trial. The protocol usually also give the 
background and rationale for the trial, but these could be provided in other protocol 
referenced documents. Throughout the ICH-GCP Guidance, the term protocol refers to 
protocol and protocol amendments. 
• Quality Assurance: 
  All those planned and systematic action that are established to ensure that the 
trial is performed and the data are generated, documented (recorded), and reported in 
compliance with GCP and the applicable regulatory requirements(s). 
• Quality Control:  
 The operational techniques and activities undertaken within the quality 
assurance system to verify that the requirements for quality of the trial related activities 
have been fulfilled. 
• Relative bioavailability:  
  Bioequivalence between ‘Drug’s, administered by the same extra vascular 
route, may be evaluated comparing pharmacokinetic parameters related to 
bioavailability, i.e., to the quantity absorbed and to the rate of the absorption process. 
Two products may be compared with one of them being considered as the reference and 
another is test. 
• Sponsor-Investigator: 
  An individual who both initiate and conducts, alone or with others, a clinical 
trial and under whose immediate direction the investigational product is administered 
to, dispensed to, or used by a subject. The term does not include any person other than 
an individual (e.g. it does not include a corporation or an agency). The obligations of a 
sponsor-investigator include both those a sponsor and those of an investigator. 
• Standard Operating Procedures: 
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  Detailed written instructions to achieve uniformity of the performance of a 
specific function. 
 
• Steady state: 
   An equilibrium state where the rate of the ‘Drug’ input is equal to the rate of 
elimination during a given dose interval.  
• Suprabioavailability: 
  If the new product displays a bioavailability appreciably larger than the 
approved product. 
• Tmax:  
 It is the time required to achieve maximum ‘Drug’ concentration in systemic 
circulation.  
• Therapeutic Equivalents: 
   A medicinal product is therapeutically equivalent with another product if it 
contains the same active substance or therapeutic moiety and, when administered to the 
same individual, shows the same efficacy and toxicity as that product, whose efficacy 
and safety has been established.  
• Validation of analytical method:  
 Validation of an analytical method is the process by which it is established, by 
laboratory studies, that the performance characteristics of the method or process meet 
the requirements for the intended application.  
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2. LITERATURE REVIEW 
   A General Introduction on Topic  
 
 
2.1. Drug  Profile : 
 
                             Cintapro contains Cinitapride hydrogen tartrate which is a new 
prokinetic agent. It is a substituted Benzamide with 5-HT2-receptor antagonist and 5-
HT4-receptor agonist activity. It is chemically described as 4-Amino-N-[3-(Cyclohexan-
1-yl-methyl)-4-piperidinyl]-2-ehoxy-5-nitrobenzamide.Its molecular formula is 
C21H30N4H4O6 with a molecular weight of 402.49  g/mol 
 
 
2.2.Structure of Cinitapride: 
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Systematic (IUPAC) name 
4-Amino-N-[3-(Cyclohexan-1-yl-methyl)-4-piperidinyl]-2-ehoxy-
5-nitrobenzamide 
Chemical data 
Formula C21H30N4H4O6 
Mol. Mass 402.49  g/mol 
Pharmacokinetic data 
Bioavailability 86% 
Protein binding Less than 36% 
Half life 5 to 7 hours 
Excretion Renal (circa 70%) 
 
 
 
 
 
 
 
2.3.Abstract:-  
 
 
               A rapid, sensitive and specific method to quantify Cinitrapride in human plasma 
using risperidone as the internal standard is described. Sample preparation involved 
simple solide phase extraction procedure. the extraction was analyzed by high 
performance liquide chromatography coupled to electrospray tandem mass 
spectrometry API-400 (LC-MS/MS).Chromatography was performed isocratically on 
thermo hypurity C18 analytical column.(50mm×4.6mm.5µm i.d ).the assay of 
cinitapride was linear calibration curve over the range 20.118 pg /ml to 2011.797 
pg/ml.plasma concentration of Cinitrapride were determined by LC-MS/MS with a 
limit of quantification of 20.118 pg/ml that allowed an appropriate characterization of 
the pharmacokinetic profile of cinitapride at the therapeutic dose. the method was 
successfully applied to the bioequivalence tablet (1.0 mg)administered as a single oral 
dose. 
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2.4.Mechanism:-  
 
 
                          Cinitapride,chemically 4-amino-N-[3-(Cyclohexan-1-yl-methyl)-4-
piperidinyl]-2-ehoxy-5-nitrobenzamide has the molecular formula C21H30N4H4O6 and 
molecular weight 402.49 g/mol.cinitapride is a drug that has against action to 
therotoninergic 5-HT2 and D2 dopaminergic receptors that has been indicated in the 
gastroesophageal reflux and in the functional disorder of  gastrointestinal motility 
treatment. The therapeutic effect of Cinitapride lies on the capacity of increasing lower 
esophageal sphineter tone and has activity, which strong gastrokinetic activity, which 
generates significant increases in the gastric emptiness: besides, through the 
serotoninergic system it stimulates the intestinal activity. the use of Cinitapride is 
efficient and safe in treatment of patients with disorders in the gastric emptiness related 
to gastroesophageal reflux and functional dyspepsia sent irritable bowel  as well as in 
individuals that present irritable bowel  syndrome .with constipation and abdominal 
pain., for determination polarographic and LC-MS/MS method  has been used. here we 
present a fast, sensitive and selective method for measuring plasma Cinitapride using 
LC-MS/MS with positive ion electrospray ionization using respridone as the internal 
standard. this method was employed in a bio-equivalence study to compare the rate and 
extend of absorption of cinitapride 1 mg tablets under fasting conditions in 12 
healthy,adult,male subjects in a randomized crossover study. 
 
2.5. Side Effects of Cinitapride:- 
• Headache    
• Upset stomach  
• Vomiting  
• Depression  
• Cough  
• Rash 
• Stomach pain  
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2.6. Drug Interaction:- 
 
                                        Anticholinergic agents like atropine, scopolamine etc.may 
reduce the action of cinitapride. Cinitapride can enhance the effect of medication that 
are used for the treatment of illnesses of the nervous system and for 
insomnia.Cinitapride can also alter the absorption of some medicines e.g. digoxin as it 
stimulates gastric emptying. 
 
Use in pregnancy, lactation and children:- 
                                      The safety of this product in pregnant women has not been 
established.Cintapro should only be used in pregnant women or women suspected of 
being pregnant only if the expected therapeutic benefits are evaluated to outweigh the 
possible risk of treatment . Treatment with Cintapro should be avoided during breast –
feeding .the safety of this product has not been established in children. 
 
 
Over dose:- 
                        There have as yet been no reports of overdose in humans. The symptoms 
of overdose include drowsiness, confusion and extrapyramidal effects.Cinitapride 
hydrogen tartrate does not cause QT prolongation. In case of excessive overdose, the 
usual measures of gastric lavage and symptomatic therapy should be applied .the extra 
pyramidal effects should be treated with antiparkinsonians,anticholinergics or 
antihistaminics with anticholinergic properties. 
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3. MATERIALS 
          AND    
                       METHODS 
 
 
 
 
 
 
 
 
 
3. MATERIALS AND METHODS 
3.1. Objective: 
 
 
    i) To evaluate the comparative oral bioavailability of Cinitapride hydrogen tartarate 
3 mg tablet (each containing Cinitapride hydrogen tartarate 3mg) with that of 
reference product cintapro 3 mg tablet (each containing Cinitapride 3 mg) of in 
healthy, adult, male, human subjects under fasting conditions. 
               ii) To assess the safety of the subjects.  
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3.2. Test Formulation (T): 
 
       Cinitapride hydrogen tartarate 3 mg tablet (each containing Cinitapride 3 mg) 
 
        Manufactured by: Zydus Cadila healthcare Ltd., Ahmedabad, India. 
 
3.3. Reference Formulation (R): 
         Cintapro 3 mg tablet (each containing cinitapride 3 mg) 
         Manufactured by: Parexel institute of clinical pharmacology, Berlin,Germany. 
 
3.4. Study Design:- 
 
 No. of Subjects: 
                                               12 + 2 (standby) 
 Blinding 
-It was an open label study. Study Monitors and subjects involved in the study 
were not blinded, as it was an open label study. 
 
-Analysts concerned were kept blinded. The randomization schedule was in the 
custody of Principal Investigator and the drug dispensing raw data record was 
under lock and key until the completion of analysis. 
 
-The randomization was balanced and the code was kept under controlled   
     access.                   
-The randomization schedule was under the custody of principal 
    investigator. 
 
 Design :- 
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An open label, randomized, two-treatment, two sequence, two period, two way 
crossover, single dose bioequivalence study of Cinitapride3 mg tablet (each 
containing Cinitapride 3mg) manufactured by comparing with cinapro3 mg tablet 
(each containing Cinitapride3 mg) in healthy, adult, male, human subjects under 
fasting conditions. 
                                                        
                                     The study flowchart, event schedule and schedule for 
blood sampling, drug dosing, safety assessment and meal for period I and II are given 
in Appendix - I, II and IV respectively. 
 
3.5.Dose :- 
 One 3mg tablet of test with 240ml water……..period(I) 
 
 One 3mg tablet of Reference with 240ml  water… .period(II) 
 
3.6. Reference Product 
 
Cintapro 3 mg is qualified as acceptable reference product by WHO. 
 
3.7. Randomizations 
The order of receiving test and reference product for each subject during the two 
periods of the study will be determined according to randomization schedule (generated 
using SAS® version 9.1.3). 
The randomization will be balanced and the code will be kept under controlled access. 
Principal investigator will have the custody of original randomization schedule. 
The analyst in the laboratory will not have the access to randomization code, till the 
end of statistical analysis. In case the standby subjects are to be analyzed, the analyst 
will analyze only those subjects as informed by the principal investigator, so that 
randomization sequence is balanced. 
The person involved in the dispensing of study drugs will be accountable for ensuring 
compliance to randomization schedule. 
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3.8. Sample Schedule:- 
 
 16 blood sample will be collected… ……….period(I) 
 
                    Predose(0.0h),0.25,0.50,0.75,1.00,1.25,1.50,2.00, 
3.00,4.00,6.00,8.00,12.00,16. 00, 20.00, 24.00 hours. 
 
 16 blood sample will be collected  … …… …..period(II)  
  
                         Predose(0.0h),0.25,0.50,0.75,1.00,1.25,1.50,2.00, 
3.00,4.00,6.00,8.00,12.00,16.00,20.00,24.00 hours. 
 
 
3.9. Diet and water :- 
a) At least 10-14 hours prior to dosing 
b) A standardized diet of approximately 2600 - 2800 calories per day will be 
provided to the study subjects on the day of dosing. (Refer Appendix - V) 
c) Subjects will be instructed to abstain from alcohol and xanthine containing 
food and beverages (chocolates, tea, coffee or cola drinks), cigarettes and 
tobacco products, for at least 48 hours, prior to dosing, for each period, and 
during their participation in the study. 
        
 
 
3.1.0. Washout Period: -    There will be washout period of at least 7 days from the   
                                               Completion of dosing between two consecutive periods. 
 
3.1.1. Sampling Procedure:- 
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Samples will be collected through an indwelling cannula placed in a forearm 
vein. The pre-dose samples will be collected within one hour prior to drug dosing. The 
post-dose samples will be collected within 2 minutes of the scheduled time where the 
end time of collection to the nearest minute would be recorded. Any deviations above 
two minutes would be recorded as protocol deviation. 
 
Intravenous indwelling cannula would be kept in place as long as required by 
injecting not more than 0.5 ml of 5 IU/ml of heparin in normal saline solution during 
the collection of multiple samples. In such a case, the blood sample would be collected 
after discarding the first 0.5 ml of heparinised blood from the tubing. Blood may also 
be withdrawn from vein by using disposable syringe and needle if the cannula is 
blocked. The proposed time point against the clock time have been and given in 
Appendix - IV, ‘Schedule for blood sampling, drug dosing, safety assessment and 
meals’. 
 
3.1.2.Handling of Samples 
 
Each blood sample withdrawn will be transferred into graduated polypropylene 
tubes containing 0.1 ml of heparin (5000 IU / 5 ml). The samples collected at each time 
point will be centrifuged at 10°C and 3200 rpm for 10 minutes to separate plasma, after 
receiving the blood samples from all the subjects. The separated plasma will be 
aliquoted in duplicate in prelabelled polypropylene tubes during each period. These 
tubes will then be transferred to a deep freezer maintained at –20±5°C for temporary 
storage and finally to a deep freezer maintained below –50°C or colder for storage. 
The tubes will be labelled with Study Number, Period Number, Date, Subject 
Number, Time Point (hrs), and Aliquot No. 
 
3.1.3. Study Termination 
The principal investigator reserves the right to terminate the study at any time 
for safety reasons or in the best interest of the subject’s welfare. The ethics committee 
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can also cancel the study for major ethical violations. The subjects would be briefed on 
the reasons for the termination and compensated adequately. 
 
3.1.4. Subject Selection, Monitoring and Assessments:- 
 
•     Eligibility Assessment 
For the purpose of this study, the following eligibility assessments will be 
carried out before enrolling any volunteer into study. 
 
I. Screening 
The screening will be carried out after taking an initial informed consent from 
volunteers for study screening procedures and will include the following: 
1. Demographic data, including sex, height and weight, BMI, nutrition status, diet, 
history of smoking, substances of abuse (Benzodiazepines, Opiates and 
Amphetamine), alcohol, blood donation and participation in drug research study 
2. Medical and treatment history including present complaints (if any), relevant past 
medical history, family history, history of any allergy to food or drug, medication 
history in the last six months 
3. Complete physical examination including recording of vital signs (B.P, Pulse, 
Temperature and respiration) and systemic examination 
4. 12-lead ECG for heart rate, rhythm and specific finding (if any) 
5. Chest X-ray (PA view) 
6. Blood and urine samples will not be sent for laboratory examination if the subject 
fails in eligibility assessment during medical examination 
 
 
 
 
II. Laboratory Parameter Investigations 
1. Complete blood count – erythrocyte count, platelet count, haemoglobin, PCV, 
leucocyte count, ESR and differential leucocyte count 
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2. Blood grouping (if previously not performed by Bioequivalence department of 
Zydus cadilaPharmaceuticals Ltd.) 
3. Biochemistry – blood glucose (fasting / random), serum: sodium, potassium, 
chloride, calcium, TG and blood cholesterol 
4. Hepatic profile – SGOT, SGPT, GGTP, Alkaline Phosphatase and serum bilirubin 
(Total, Direct, Indirect) 
5. Renal profile – serum creatinine and serum urea 
6. Urine - physical examination, chemical examination, microscopic examination 
and substances of abuse (benzodiazepines, opiates and amphetamine) 
 
III. Trial Assessments :- 
    The following will be recorded during the conduct of the study -     
¾ Check in and check out details 
¾ Vital details 
¾ Meal distribution details 
                            -Time of dose administration 
                            -Target and actual blood sampling times 
                            -Concomitant therapy changes 
                            -Adverse events. 
 
IV. Safety Assessments :- 
       Recording of vital signs and clinical examination :- 
¾ A doctor will be available within the clinical facility whenever the subjects 
are housed (from check-in to checkout in each period).A physician will 
always be available on call during the study period. 
¾ Period (I) :-Vital signs like sitting blood pressure and radial pulse will be 
measured and recorded during subject check-in ,prior to administration of 
dose ,1.00,2.00,4.00, and 12.00 hours after administration of dose and at 
checkout. 
¾ Clinical examination of all the subjects will be done at the time of check-in 
and at checkout and /or at termination of  the study .clinical examination 
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may also be done at any time during the conduct of the study if the attending 
physician feels necessary.In case of abnormality in vital signs or 
not.subjects will be questioned for well being at the time of clinical 
examinations and recording of vital signs. 
¾ Laboratory assessments will be at the study at the time of 
screening.Hematology ,renal function,hepatic function will be done at the 
end of the study(last sample of period II). 
 
V. Inclusion Criteria :- 
 
¾ Male subjects aged between 18 and 45 years.(both inclusive) 
¾ Subjects weight within ± 15% of the ideal height-weight chart of life 
insurance corporation of India for non-medical cases ability to communicate 
effectively with study personnel . 
¾ Ability to communicate effectively with study personnel. 
¾ Willingness to adhere to the protocol requirements. 
¾ Be able to give consent for participation in the trial. 
¾ Normal health as determined by personal medical history ,clinical 
examination  and laboratory examination data during screening (within the 
clinically acceptable range ) 
 
 
VI. Exclusion Criteria :- 
¾ History of hypersensitivity to cinitapride or any of  the product components . 
¾ History or presence of cardiovascular ,respiratory ,hepatic ,renal, 
gastrointestinal,Endocrine,immunological,dermatological,neurologic,psychi
atric disease or any other body system involvement. 
¾ History or presence of significant alcoholism or drug abuse within the past 
one-year. 
¾ History or presence of significant smoking (more than 10 cigarettes per day 
) or consumption of tobacco products. 
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¾ Difficult with donating blood. 
¾ Blood pressure less than 100/60 (systolic/diastolic) mm Hg or more than 
140/90 mm Hg . 
¾ Pulse less than 55/minute or more than 110/minute . 
¾ Febrile 
¾ Any ECG or X-Ray abnormalities during screening. 
¾ Major illness during 3 months before the screening period. 
¾ Presence of clinically significant abnormal laboratory values during 
screening . 
¾ Subject who have participated in drug research studies within past 3 months 
. 
¾ Subject who have donated one unit (350 ml) of blood I the past 3 months . 
¾ Subject who are found positive in alcohol breathe test and urine test for drug 
of abuse at the time of check in during both the periods . 
 
VII. Withdrawal Criteria :- 
 
               The investigator may withdraw a subject from the study for any of the following- 
 
¾ The subject suffers from significant intercurrent illness or undergoes surgery 
during the course of the study . 
¾ Any subject found to have entered the study in violation of this protocol . 
¾ Any subject who requires the use of an unacceptable concomitant 
medication . 
¾ If it is felt in investigator’s best interest to continue . 
¾ Any subject who wishes to withdraw his consent  
 
 
3.1.5. Restriction 
•   Dosing 
 
 
 
49 
           After overnight fasting of at least of 10 hours, test or reference 
products will be administered at 0.00 hours to the subjects as per the 
randomization schedule with 240 ml of water under the supervision of the 
Medical Officer during each period of the study. 
            Compliance for dosing after drug administration will be assessed 
by examination of the oral cavity of the subjects by trained study personnel 
immediately after dose administration in each period. 
              However, measurement of cinitapride concentrations in the 
plasma will be carried out for 12 subjects, successfully completing both the 
periods of the study. The plasma samples of standby subjects will be analysed in 
case of dropouts. 
 
    3.1.6. Clinical Residency:- 
 
      The clinical phase of the study will be carried out at the clinical facility of 
Bioequivalence department of Zyduscadila Healthcare Ltd. Subjects will be admitted 
and housed in the clinical facility prior to 11.00 hours before the administration of the 
dose during each period of the study. In each period, subjects will be discharged after 
24.00 hours post dose, if not suffering from any adverse events. In case of any adverse 
events, the subjects will be kept under observation until the abatement of the events. 
 
3.1.7.Pharmacokinetic Analysis:- 
 
Pharmacokinetic parameters of Cinitapride will be calculated using the SAS® 
system version 9.1.3: 
Tmax: Time of maximum measured plasma concentration. If maximum value occurs at 
more than one point, Tmax is defined as the first point with this value in each period. 
Cmax: Maximum measured plasma concentration following each treatment. 
AUC0–t: The area under the plasma concentration versus time curve from time zero to 
the last measurable concentration, as calculated by the linear trapezoidal method. 
 
 
 
50 
AUC0– ∞: The area under the plasma concentration versus time curve, from zero to 
infinity. AUC0-∞ is calculated as the sum of the AUC0-t plus the ratio of the last 
measurable concentration to the elimination rate constant. 
Kel: Apparent first order elimination or terminal rate constant calculated from semi log 
plot of the plasma concentration versus time curve. The parameters will be calculated 
by linear least square regression analysis using at least the last three non-zero plasma 
concentration. 
T1/2: Time required for the plasma drug concentration to decrease to one half. 
 
3.1.8. Analysis of Variance (ANOVA) 
 
The log-transformed pharmacokinetic parameters (Cmax, AUC0-t, AUC0-∞) 
will be analysed using an ANOVA model with the main effects of sequence, 
subject nested within sequence, period and ‘treatment’. A separate ANOVA 
model will be used to analyze each of the parameters. A 5% level of significance 
will be used for with-in subject comparison (i.e., period, ‘treatment’) and 
between-subject comparison (i.e., sequence). Each analysis of variance will 
include calculation of mean square error, coefficient of variance and the 
associated degree of freedom. 
 
3.1.9. 90% Confidence Intervals 
 
A 90% confidence interval for the ratio of both the products averages 
(geometric means) will be calculated by first calculating the 90% confidence 
interval for the differences in the averages (least square means) of the log-
transformed data and then taking the antilogarithms of the obtained confidence 
limits. 
 
 
 
 
 
51 
3.2.0. Bioequivalence:- 
 
               The 90 % confidence interval for Cmax, AUC0-t and AUC0-∞ of 
Cinitapride will form the basis for concluding the equivalence of Cinitapride in 
product R and T. If the point estimate of the ratio and the confidence intervals 
are entirely included in the range of 80 – 125 % for AUC0-t, AUC0–∞ and Cmax 
log-transformed then the treatments will be claimed to be bioequivalent.  
 
3.2.1. Power Calculations 
 
       For analyses using the log-transformed data, the power of the ANOVA 
model to detect the ratio of the two products averages being equal to 125% (or 
80%) at the 5 % significance level, will be calculated. 
 
         3.2.2. Ethical Consideration and Issues:- 
 
• Independent Ethics Committee 
 
                 This study will be carried out as per the ICH Guidelines for 
Good Clinical Practice (GCP) and the principles of Declaration of Helsinki 
(Tokyo, October 2004). The Independent Ethics committee shall review the 
protocol and the informed consent form for the study and no study specific 
procedure will be carried out until written approval is obtained from the 
committee. Once the study will complete, a summary of study will be send to the 
IEC regarding the conduct of study and occurrence of any adverse events. 
 
• Informed Consent Form 
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                   Designated personnel will inform the subjects before the 
initiation of the study.  Subjects will be required to understand and sign and date 
a consent form prior to initiation of any study specific activity. A copy of the 
signed informed consent form will be given to the respective volunteers for their 
reference and one sample copy will be provided in the final report. The original 
signed and dated ICF will be archived at Bioequivalence department of 
Zyduscadila Healthcare Ltd. 
 
• Subject Compensation 
The subjects will be compensated for the overall inconvenience borne during 
the study.  
In case of dropouts / withdrawal of a subject before completion of the 
study, the amount of proportionate compensation to the dropout / withdrawal 
subject will be as follows: 
 
 
Sr. 
No. Reasons of Withdrawal from the Study Compensation 
1. Principal Investigator / Medical Officer withdraws the subjects from the study based on medical decision. Full payment 
2. After the initiation of the study, subject withdraws on his own free will 
50% 
proportionate 
participation 
dues 
3. 
The subject is withdrawn from the study on 
humanitarian grounds, with the permission of the 
Principal Investigator / Medical Officer. 
100% 
proportionate 
participation 
dues 
4. 
Subject is dropped from the study due to violation of 
requirements of the study by the Principal Investigator 
/ Medical Officer after signing the Informed Consent 
Form but before receiving any medications  
No payment 
5. 
Subject is withdrawn from the study by the Principal 
Investigator / Medical Officer because of willful 
misinformation on present and /or past medical 
No payment 
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illness/history. 
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                                          APPENDIX - I 
1.0                                STUDY FLOW CHART 
Screening 
  
 
Eligibility Criteria 
 
Subject Selection (N = 12 + 2) 
 
 
 
 
R                                                                                                      T 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Randomization 
Period I 
 
 
Treatment R (6 + 1) Treatment T (6 + 1) 
Washout 
(At least 7 Days)
Period II 
 
 
 
Treatment T (6 + 1) Treatment R (6 + 1) 
 
Crossover
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N – Number of subjects, R – Reference Product, T – Test Product 
 
APPENDIX - II 
EVENT SCHEDULE 
Pe
ri
od
 I 
Pe
ri
od
 
II
 
Sr
. N
o.
 
Requirement 
Sc
re
en
in
g 
C
he
ck
-in
 
C
he
ck
-
ou
t 
C
he
ck
-in
 
C
he
ck
-
ou
t 
1. Written informed consent  *     
2. Demographics  *     
3. Medical and treatment history *     
General and systemic * * * * * 
Vital signs * * * * * 
12 lead ECG *    * 
4. 
Medical 
examinat
ion 
Chest X-ray PA view *     
CBC (erythrocyte count, PCV, 
ESR, platelet count, Total and 
differential leucocyte count) 
*    * 
LFT (SGOT, SGPT, Alk. 
Phosphatase and bilirubin 
(direct, indirect and total) 
*    * 
TG, blood cholesterol *     
GGTP *     
Serum: Sodium, potassium, 
chloride, calcium and blood 
glucose (fasting/random) 
*    * 
RFT (serum creatinine and 
serum urea) *    * 
Urine (Routine) *     
Substances of abuse 
(Benzodiazepine, opiates and 
amphetamine) 
*     
5. 
Clinical 
laborator
y tests 
Infectious diseases  *     
6. (SQ)  * * 
7. Drug administration  * * 
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8. Blood sampling  *** *** 
CBC: Complete blood count           LFT: Liver function test      RFT: Renal function test 
SQ: Subject questionnaire   
ECG and clinical laboratory tests will be performed to cater to the post study safety 
assessments at the end of period II. 
APPENDIX - III 
SCHEDULE FOR BLOOD SAMPLING, DRUG DOSING, SAFETY 
ASSESSMENT AND MEALS 
2.0 DOSE ADMINISTRATION AND BLOOD SAMPLING 
Time 
Dose 
Admi
nistrat
ion 
Blood Sampling 
Time 
Relative 
to Dose 
Adminis
tration 
(Hrs) 
0.00 
– 
1.00 
to 
0.00 
0.
25
 
0.
50
 
0.
75
 
1.
00
 
1.
25
 
1.
50
 
2.
00
 
3.
00
 
4.
00
 
6.
00
 
8.
00
 
12
.0
0 
16
.0
0 
20
.0
0 
24
.0
0 
Clock 
Time in 
Hrs 
(Days) 
0800 
(D 1) 
070
0 to 
080
0 
(D1
) 
08
15
 (D
 1
) 
08
30
 (D
 1
) 
08
45
 (D
 1
) 
09
00
 (D
 1
) 
09
15
 (D
 1
) 
09
30
 (D
 1
) 
10
00
 (D
 1
) 
11
00
 (D
 1
) 
12
00
 (D
 1
) 
14
00
 (D
 1
) 
16
00
 (D
 1
) 
20
00
 (D
 1
) 
00
00
 (D
 2
) 
04
00
 (D
 2
) 
08
00
 (D
 2
) 
3.0 SAFETY ASSESSMENT 
Time Vitals 
Subject 
Questionnaire (SQ) 
Time 
Relative to 
Dose 
Administr
ation (Hrs) 
Prior 
to –
11.00 
–1.00 
to 
0.00 
1.00 5.50 9.00 24.00 2.50 11.00 24.00 
Clock 
Time in 
Hrs (Days) 
Prior 
to 
2100 
(D 0) 
0700 
to 
0800 
(D 1) 
0900 
(D 1) 
1330 
(D 1) 
1700 
(D 1) 
0800 
(D 2) 
1030 
(D 1) 
1900 
(D 1) 
0800 
(D 2) 
4.0 MEALS 
Meal Dinner Lunch Snacks Dinner 
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Time Relative to Dose 
Administration (Hrs) – 11.00 4.00 8.00 13.00 
Clock Time in Hrs 
(Days) 2100 (D 0) 1200 (D1) 1600 (D1) 2100 (D1) 
 
 
 
 
 
 
 
 
 
 
 
 
5. RESULTS AND  
                  DISCUSSION 
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           5. RESULTS AND DISCUSSION 
 
                The individual and mean plasma Cinitapride concentrations for 
reference and test products are presented in Table 1 and 2 respectively. The summary 
statistics for untransformed and log-transformed pharmacokinetic parameters of 
reference and test products for Cinitapride are presented in Table 3 and 4 respectively. 
The comparative evaluation of various mean pharmacokinetic parameters of Cinitapride 
for reference and test products is presented in Table 5. 
                    The comparative linear and semi-log plots of mean plasma 
Cinitapride concentration-time profiles of reference and test products are presented in 
Figures 1 to 2 respectively. The comparative linear and semi-log plots of individual 
plasma Cinitapride concentration-time profiles of reference and test products are 
presented in Figures 03 to 24. 
 
¾ Cinitapride :- 
 
 The arithmetic mean Tmax of the test product is 1.688 hours and that of 
the reference product is 1.125 hours. 
 
 The arithmetic mean Cmax of the test product is 2851.06167 ng/ml and 
that of the reference product is 2909.05833 ng/ml. 
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 The arithmetic mean AUC0-t of the test product is 13169.69896 ng*hr/ml 
and that of the reference product is 13059.02865 ng*hr/ml. 
 
 The arithmetic mean AUC0-∞ of the test product is 13471.85806 
ng*hr/ml and that of the reference product is 13348.27033 ng*hr/ml. 
 
 
The % Bioavailability for the untransformed pharmacokinetic parameters is as 
follows: 
Cmax : 98.01% 
AUC0-t : 100.85% 
AUC0-∞ : 100.93% 
The Intra C.V. % for log-transformed pharmacokinetic parameters is as follows: 
Cmax :  21.68% 
AUC0-t :  15.00% 
AUC0-∞ : 14.50% 
 
 
The Power (%) for log-transformed pharmacokinetic parameters is as follows: 
Cmax :  62.31% 
AUC0-t :  90.94% 
AUC0-∞ :  92.52% 
 
            The 90% confidence intervals for log-transformed pharmacokinetic parameters 
are: 
Cmax :  83.21% - 114.26% 
AUC0-t :  90.73% - 113.14% 
AUC0-∞ : 91.11% - 112.79% 
 
The ratio of  mean AUC0-t  to mean AUC0-∞ for test is 97.76% and for reference is 
97.83%. 
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6. CONCLUSION 
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6. CONCLUSION 
 
Bioequivalence is evaluated by three pharmacokinetic parameters viz., AUC, 
Cmax and Tmax out of which AUC and Cmax are main parameter for evaluation. 
 
The pharmacokinetic parameters (AUC and Cmax) of Cinitapride are within the 
acceptable limits of bioequivalence 80% - 125%. 
 
Hence, it is concluded that single dose bioequivalence study of Cinitapride 3 mg 
tablet (each containing Cinitapride 3 mg) is bioequivalent with Cintpro 3 mg tablet 
(each containing Cinitapride 3 mg) 
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TABLE 1 
Individual and Mean Plasma Cinitapride Concentrations (ng/mL) for Reference Product (R) 
Sub. Seq 
0.00 
Hrs 
0.25 
Hrs 
0.50 
Hrs 
0.75 
Hrs 
1.00 
Hrs 
1.25 
Hrs 
1.50 
Hrs 
2.00 
Hrs 
3.00 
Hrs 
4.00 
Hrs 
6.00 
Hrs 
8.00 
Hrs 
12.00 
Hrs 
16.00 
Hrs 
20.00 
Hrs 
24.00 
Hrs 
1 RT 0.00 83.23 1200.74 3812.02 4036.21 3710.65 3300.19 2831.14 2172.77 1786.02 1620.60 881.15 277.04 116.77 65.83 BLQ 
2 RT 0.00 0.00 479.46 3164.28 3009.00 2755.60 2541.75 1793.72 1748.48 1091.16 834.51 523.32 282.95 138.00 91.55 60.42 
3 TR 0.00 275.64 1254.27 2325.25 2585.93 2297.58 2181.84 1640.96 1481.42 1276.48 869.15 516.01 220.55 112.37 70.84 50.13 
4 TR 0.00 728.31 1512.44 1519.17 1232.12 1171.34 1094.65 1048.21 811.04 621.34 280.72 195.32 95.27 61.55 50.72 BLQ 
5 RT 0.00 238.97 1604.67 3262.41 2744.20 2282.72 2191.26 1715.07 1609.38 1312.21 639.67 336.90 135.62 73.13 BLQ BLQ 
6 TR 0.00 57.95 1495.36 3449.42 4511.30 4585.11 3825.49 3038.42 2612.26 2221.32 1206.43 766.74 306.31 131.22 76.22 59.78 
7 TR 0.00 0.00 427.15 1068.45 2087.12 3032.60 3937.48 3674.47 1902.13 1814.56 937.85 557.30 202.58 97.02 66.66 55.36 
8 RT 0.00 277.57 1077.66 1079.61 1196.32 1342.14 1474.34 1825.74 1190.43 916.68 465.73 288.26 125.54 71.54 BLQ BLQ 
9 TR 0.00 BLQ 407.33 619.76 855.22 1034.20 1209.06 1646.77 1608.75 1441.28 750.81 420.48 127.71 54.37 BLQ BLQ 
11 RT 0.00 335.03 2246.97 2482.35 2513.16 2397.63 2362.65 2159.49 2000.98 1512.26 871.62 554.02 226.78 122.66 68.01 50.77 
12 TR 0.00 77.97 1283.86 1754.86 1665.25 1653.00 1679.64 1503.13 1029.60 1223.06 947.65 571.80 202.86 106.82 67.41 61.48 
14 RT 0.00 95.94 2028.99 4077.58 3668.76 3266.46 2863.92 2406.94 2161.99 1867.44 805.83 421.89 145.27 56.17 BLQ 0.00 
Mean 0.00000 197.32818 1251.57500 2384.59667 2508.71583 2460.75250 2388.5225 2107.00500 1694.1025 1423.65083 852.54750 502.76583 195.70667 95.13500 69.65500 48.27714 
S.D. 0.000000 212.145339 593.128150 1172.585762 1166.82587 1078.80184 954.917675 749.979649 519.283280 448.339962 339.369411 191.923405 70.019128 30.378408 11.425382 21.773749 
Minimum 0.00 0.00 407.33 619.76 855.22 1034.20 1094.65 1048.21 811.04 621.34 280.72 195.32 95.27 54.37 50.72 0.00 
Maximum 0.00 728.31 2246.97 4077.58 4511.30 4585.11 3937.48 3674.47 2612.26 2221.32 1620.60 881.15 306.31 138.00 91.55 61.48 
C.V.% - 107.51 47.39 49.17 46.51 43.84 39.98 35.59 30.65 31.49 39.81 38.17 35.78 31.93 16.40 45.10 
Note: Samples having concentration below 50.02 ng/mL were set to zero and reported as BLQ. 
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TABLE 2 
Individual and Mean Plasma Cinitapride Concentrations (ng/mL) for Test Product (T) 
Sub. Seq 
0.00 
Hrs 
0.25 
Hrs 
0.50 
Hrs 
0.75 
Hrs 
1.00 
Hrs 
1.25 
Hrs 
1.50 
Hrs 
2.00 
Hrs 
3.00 
Hrs 
4.00 
Hrs 
6.00 
Hrs 
8.00 
Hrs 
12.00 
Hrs 
16.00 
Hrs 
20.00 
Hrs 
24.00 
Hrs 
1 RT 0.00 227.50 1413.74 1931.12 2465.33 3169.89 4185.44 4172.16 2943.39 2200.20 1442.90 780.81 264.95 111.10 58.83 BLQ 
2 RT 0.00 80.67 597.10 1378.33 2037.09 2354.20 3222.08 3253.12 2174.52 1702.92 903.40 588.43 248.93 119.78 72.07 64.32 
3 TR 0.00 154.11 1755.32 2742.07 2324.74 1962.76 1694.71 1369.98 1037.02 1007.90 567.75 361.53 162.30 72.14 BLQ BLQ 
4 RT 0.00 0.00 884.98 1356.12 1432.17 1645.78 1529.21 1820.80 1440.45 1060.66 559.67 343.01 132.07 64.40 BLQ BLQ 
5 RT 0.00 0.00 BLQ 393.41 2377.69 3028.66 2396.82 1699.86 1270.44 1080.14 503.18 341.79 118.09 55.54 BLQ BLQ 
6 TR 0.00 55.30 556.53 2795.52 3989.27 3997.69 3261.73 2776.46 2449.11 1717.82 1028.35 732.78 294.73 125.61 90.46 68.96 
7 TR 0.00 0.00 1336.54 2022.23 1898.41 2036.19 2136.86 1959.68 2037.27 1443.02 742.30 415.41 212.99 110.93 78.61 67.61 
8 RT 0.00 638.13 1147.07 1266.31 1135.14 1130.90 1228.77 1363.00 1032.04 851.18 418.58 219.84 115.94 75.94 60.42 54.03 
9 TR 0.00 305.00 811.67 1193.18 1471.79 1461.62 1404.62 1167.44 1014.83 1482.85 1004.70 653.58 167.74 67.96 BLQ BLQ 
11 RT 0.00 228.28 2043.28 4110.56 4383.50 4668.70 4041.81 3120.64 2133.37 1727.19 978.72 610.96 234.56 110.55 66.13 BLQ 
12 TR 0.00 127.54 756.73 1213.11 1628.89 1777.17 1789.94 2026.85 1907.74 1748.00 1116.87 668.92 279.32 122.02 73.70 57.80 
14 RT 0.00 286.88 2411.80 3506.70 3190.43 2771.94 2299.53 2226.96 2580.14 1605.54 761.81 382.29 125.85 54.56 BLQ 0.00 
Mean 0.00000 175.28417 1246.79636 1992.38833 2361.20417 2500.45833 2432.62667 2246.41250 1835.02667 1468.95167 835.68583 508.27917 196.45583 90.87750 71.46000 52.12000 
S.D. 0.000000 182.729471 612.786217 1091.425823 1020.394119 1065.080659 1016.17583 909.074853 663.324219 396.297044 299.270802 184.100260 67.041724 27.924913 11.009992 26.171628 
Minimum 0.00 0.00 556.53 393.41 1135.14 1130.90 1228.77 1167.44 1014.83 851.18 418.58 219.84 115.94 54.56 58.83 0.00 
Maximum 0.00 638.13 2411.80 4110.56 4383.50 4668.70 4185.44 4172.16 2943.39 2200.20 1442.90 780.81 294.73 125.61 90.46 68.96 
C.V.% - 104.25 49.15 54.78 43.21 42.60 41.77 40.47 36.15 26.98 35.81 36.22 34.13 30.73 15.41 50.21 
Note: Samples having concentration below 50.02 ng/mL were set to zero and reported as BLQ. 
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TABLE 3 
Summary Statistics of Untransformed Pharmacokinetic Parameters for Cinitapride 
 
Product / Statistics Cmax (ng/mL) 
AUC0-t 
(ng*hr/mL)
AUC0-∞ 
(ng*hr/mL)
Tmax 
(hr) 
Kel 
(1/hr) 
T1/2 
(hr) 
       
Arithmetic Mean (R) 2909.05833 13059.03000 
13348.2691
7 1.125 0.20942 3.40972
S.D. 1086.477662 4080.384295 
4082.64444
8 0.4707 0.039520 0.588224
C.V. (%) 37.35 31.25 30.59 41.84 18.87 17.25 
Geometric Mean 2714.10276 12440.40765 
12744.2185
4 1.049 0.20622 3.36055
       
Arithmetic Mean (T) 2851.06167 13169.70000 
13471.8583
3 1.688 0.21624 3.34365
S.D. 1102.527787 4022.028471 
4024.84392
5 0.8603 0.045064 0.739516
C.V. (%) 38.67 30.54 29.88 50.98 20.84 22.12 
Geometric Mean 2646.32947 12604.31562 
12919.1915
1 1.525 0.21179 3.27209
       
Ratio of Geometric 
Means (T/R) % 97.50 101.32 101.37 - - - 
       
% Bioavailability 98.01 100.85 100.93 - - - 
       
Ratio (%) for Mean AUC0-t to Mean AUC0-∞ 
Reference (R) 97.83% 
Test (T) 97.76% 
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TABLE 4 
 
Summary Statistics of Log-Transformed Pharmacokinetic Parameters for 
Cinitapride 
 
 
Product / Statistics Cmax (ng/mL) 
AUC0-t 
(ng*hr/Ml) 
AUC0-∞ 
(ng*hr/mL) 
    
Least Square Mean (R) 7.90621670 9.42870501 9.45283309 
    
Least Square Mean (T) 7.88092885 9.44179446 9.46646915 
    
ANOVA Summary (Results : P- Values)    
Sequence 0.2215 0.6051 0.6074 
Period 0.5586 0.9947 0.9936 
Treatment 0.7784 0.8341 0.8216 
    
Intra C.V. % 21.68 15.00 14.50 
Power % 62.31 90.94 92.52 
MSE 0.045922 0.022237 0.020813 
D.F. 10 10 10 
    
90% CI for T/R Ratio    
Lower Limit (%) 83.21 90.73 91.11 
Upper Limit (%) 114.26 113.14 112.79 
Noste: Log-transformed data are calculated using natural log. 
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TABLE 5 
 
Pharmacokinetics Parameters for Cinitapride 
 
Reference Product Tes
Sub. Seq. Cmax 
(ng/mL) 
AUC0-t 
(ng*hr/mL) 
AUC0-∞ 
(ng*hr/mL) 
Tmax 
(hr) 
Kel 
(1/hr) 
T1/2 
(hr) 
Cmax 
(ng/mL) 
AUC0-t 
(ng*hr/mL) 
AU
(ng*
1 RT 4036.21 19014.99 19314.22 1.00 0.2200 3.1501 4185.44 20094.34 203
2 RT 3164.28 13445.57 13795.82 0.75 0.1725 4.0172 3253.12 15452.72 158
3 TR 2585.93 12631.35 12915.40 1.00 0.1765 3.9268 2742.07 9460.19 978
4 TR 1519.17 6356.67 6630.41 0.75 0.1853 3.7402 1820.80 9105.71 937
5 RT 3262.41 11197.74 11492.18 0.75 0.2484 2.7902 3028.66 9129.46 934
6 TR 4585.11 20070.04 20373.85 1.25 0.1968 3.5220 3997.69 17616.07 179
7 TR 3937.48 15633.57 15918.37 1.50 0.1944 3.5652 2136.86 12772.40 131
8 RT 1825.74 8172.44 8499.62 2.00 0.2187 3.1694 1363.00 7735.18 811
9 TR 1646.77 9570.91 9771.01 2.00 0.2717 2.5504 1482.85 10729.25 109
11 RT 2513.16 14445.41 14720.84 1.00 0.1843 3.7596 4668.70 17741.91 180
12 TR 1754.86 11472.16 11851.05 0.75 0.1623 4.2709 2026.85 14353.23 146
14 RT 4077.58 14697.51 14896.46 0.75 0.2823 2.4546 3506.70 13845.94 140
Mean 2909.05833 13059.03000 13348.26917 1.125 0.20942 3.40972 2851.06167 13169.70000 134
Geometric Mean 2714.10276 12440.40765 12744.21854 1.049 0.20622 3.36055 2646.32947 12604.31562 129
S.D. 1086.477662 4080.384295 4082.644448 0.4707 0.039520 0.588224 1102.527787 4022.028471 402
Minimum 1519.17 6356.67 6630.41 0.75 0.1623 2.4546 1363.00 7735.18 811
Maximum 4585.11 20070.04 20373.85 2.00 0.2823 4.2709 4668.70 20094.34 203
C.V. % 37.35 31.25 30.59 41.84 18.87 17.25 38.67 30.54 29.8
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Figure-1  :    Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No =1 
 
Figure-2 :    Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =1                                        
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Figure-3 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =2 
                                                       
 
Figure-4  :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No =2                                         
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Figure-5 :    Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No =3 
                                                                    
      
Figure-6     Comparative semi Log  plot of Cinitapride Plasma Concentration (ng/ml) Vs Time .  Subject No=3 
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Figure-7  :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No =4                                              
 
Figure-8 :    Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =4                                         
 
 
 
 
 
73 
Figure-9 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =5                                               
 
Figure-10 :   Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No 
=5                                                              
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Figure-11 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =6                                             
 
Figure-12 :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =6 
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Figure-13 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =7                                             
 
Figure-14 :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No 
=7                                                        
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Figure-15 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =8                                              
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Figure-16 :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No 
=8                                                               
 
 
Figure-17 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No =9                                             
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Figure-18 :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No 
=9 
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Figure-19 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =11                                           
 
Figure-20 : Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No 
=11                                                                
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Figure-21 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =12                                            
 
 
Figure-22 :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No 
=12                                                  
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Figure-23 :  Comparative Linear Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours). Subject No =14                                           
 
Figure-24 :  Comparative Semi Log Plot of Cinitapride Plasma Concentration (ng/ml) Vs (Hours).  Subject No 
=14                                                     
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